Skip to content Skip to footer
Viewpoints_Dr. Barbara Delage_Dr. Nicholas Kassebaum

Dr. Barbara Delage and Dr. Nicholas Kassebaum Shares Insights on Malnutrition-related Deaths

Shots: Dr. Barbara Delage talked about the key findings from the new study on malnutrition-related deaths. She also spoke about the birth condition, Orofacial cleft Dr. Nicholas Kassebaum spoke about how malnutrition-related deaths could be prevented in children living with a cleft The study was conducted in collaboration with Smile Train and the Institute for…

Read more

Viewpoints_Michael Irizarry

Michael Irizarry, SVP, Clinical Research, Eisai Shares Insights from the Clinical Data of Lecanemab Presented at AAIC

Shots: Michael talked about the new data from its Alzheimer’s pipeline at the Alzheimer’s Association International (AAIC) Michael also highlighted the study design of the P-II & P-III trial evaluating lecanemab The interview gives an understanding of  Eisai’s human health care (hhc) concept which provides innovative products with high unmet medical needs to target diseases…

Read more

Viewpoints_Brian Quigley

Brian Quigley, CEO at Qnovia Shares Insights on Respira Technologies Rebranded as Qnovia

Shots: Brian spoke about why Respira Technologies has been rebranded as Qnovia Brian also talked about how Qnovia is working to advance its first inhalable prescription smoking cessation therapy and its applications The interview summarizes how this rebranding will accelerate Qnovia’s technology and products from others in the biotechnology space  Smriti: Would you please start off…

Read more

Viewpoints_Dr. Volker Knappertz

Dr. Volker Knappertz, EVP R&D, Aurinia Shares Insights on LUPKYNIS MAA from EMA

Shots: Volker spoke about the granting of marketing authorization by EC to treat adults with active lupus nephritis.The approval was based on the results of the P-III AURORA study  Volker also talked about the collaboration between Aurinia and Otsuka Pharmaceutical for the development and commercialization of LUPKYNIS The interview gives an understanding of how Aurinia…

Read more

Viewpoints_Dr. Robert Kowal

Dr. Robert Kowal, Vice President at Medtronic Shares Insights on a New Clinical Study on Micra AV Leadless Pacing Performance

Shots: Robert spoke about the publication of the new study in the Heart Rhythm Journal about the Micra AV leadless pacemaker and how it is an effective therapy for patients with atrioventricular (AV) block  Robert talked about the study design and the key findings from the study evaluating Medtronic’s Micra AV device  The interview gives an understanding…

Read more

Viewpoints_Patrick Mooney

Patrick Mooney, CEO at SpyGlass Pharma, Shares Insights from the 3-Month Data of its Innovative Drug Delivery Platform for Chronic Eye Conditions

Shots: Patrick spoke about the 3-month data from the First-in-Human glaucoma treatment trial of Spyglass’ innovative  drug delivery platform that helps in lowering intraocular pressure in patients with glaucoma or ocular hypertension Patrick also talked about the study design and key findings from the First-in-Human glaucoma treatment trial The interview gives an understanding of Spyglass’…

Read more

Viewpoints_Dr. Navdeep Tangri_Helen Yeh

Dr. Navdeep Tangri & Helen Yeh Shares Insights from the Data Presented at ASN Kidney Week 2022 on the Importance of Earlier Screening & Diagnosis of Chronic Kidney Disease

Shots: Dr. Navdeep spoke about the data presented at the ASN Kidney Week 2022 emphasizing on the urgent need for early screening of chronic kidney disease Helen Yeh talked about the treatment of CKD with Farxiga. She also focused on the patient support programs by AstraZeneca for the early diagnosis and screening of patients The…

Read more

Viewpoints_Dr. Susana Banerjee

Dr. Susana Banerjee, Medical Oncologist at The Royal Marsden Shares Insights from the SOLO-1 P-III Trial of Lynparza in Patients with BRCA Mutated Ovarian Cancer

Shots: Dr. Susan talked about the results from the SOLO-1 P-III trial of Lynparza in patients with BRCA mutated (BRCAm) newly diagnosed advanced ovarian cancer presented at ESMO’22 Dr. Susan also spoke about the overall survival of this 7-year follow-up study.The 7-year follow-up of SOLO-1 showed that olaparib provided a clinically meaningful improvement in OS…

Read more

Viewpoints_Dr. Bill La Via

Dr. Bill La Via, Medical Director at Sanofi Shares Insights from the Findings that Support the Need of Protecting Infants from Respiratory Syncytial Virus (RSV)

Shots: Bill spoke about Respiratory Syncytial Virus and how it can severely affect infants' health Bill also talked about the 14 studies on RSV published in the Journal of Infectious Diseases (JID) The interview gives an understanding of how Sanofi’s vision to develop innovative solutions to help reduce the burden of RSV on infants, families,…

Read more